ABSTRACT: Graft failure occurs in a sizeable proportion of coronary artery bypass conduits. We herein review relevant current evidence to give an overview of the incidence, pathophysiology, and clinical consequences of this multifactorial phenomenon. Thrombosis, endothelial dysfunction, vasospasm, and oxidative stress are different mechanisms associated with graft failure. Intrinsic morphological and functional features of the bypass conduits play a role in determining failure. Similarly, characteristics of the target coronary vessel, such as the severity of stenosis, the diameter, the extent of atherosclerotic burden, and previous endovascular interventions, are important determinants of graft outcome and must be taken into consideration at the time of surgery. Technical factors, such as the method used to harvest the conduits, the vasodilatory protocol, the storage solution, and the anastomotic technique, also play a major role in determining graft success. Furthermore, systemic atherosclerotic risk factors, such as age, sex, diabetes mellitus, hypertension, and dyslipidemia, have been variably associated with graft failure. The failure of a coronary graft is not always correlated with adverse clinical events, which vary according to the type, location, and reason for failed graft. Intraoperative flow verification and secondary prevention using antiplatelet and lipidlowering agents can help reducing the incidence of graft failure.
L ong-term graft patency is the primary aim of coronary artery bypass surgery (CABG). Graft failure is a complex, multifactorial event that occurs in a substantial proportion of CABG conduits. Although intimal hyperplasia and minor graft stenosis are commonly observed in grafts years after surgery, the major contributors to both early and late occlusion remain unclear. Additionally, graft narrowing can significantly limit blood flow to the revascularized area of the heart, leading to poor outcomes.
With the aim of contributing to a better understanding of this phenomenon, we present a review of the current evidence on the biological, technical, and local factors that predispose to graft failure. In addition, we review the published evidence on the clinical implications of graft failure and discuss possible preventive strategies.
LITERATURE SEARCH
The ATLANTIC Alliance (Arterial Grafting International Consortium) is an international group of experts in CABG biology, pharmacology, and surgery with a particular focus on the use of arterial grafts. In November 2016, the members of ATLANTIC searched PubMed using the terms "graft patency," "graft failure" coupled with "coronary surgery," "myocardial revascularization," "coronary artery bypass," "CABG," "morphology," "vascular biology," "intraoperative detection," and "prevention." Relevant abstracts were reviewed and PubMed "related articles" function was used for all included manuscripts. References from selected studies were cross-checked. After collegial discussion, the most important papers were selected and form the basis of the present review.
It must also be noted that considerable heterogeneity in the definition of graft failure exists among the different studies. Graft stenosis, thrombosis, occlusion, and acute and chronic failure have often been considered together in the published series. Consequently, every effort to distinguish among the different pathological and clinical entities has been made by the authors, but a clear distinction was not always possible.
PATENCY OF DIFFERENT CONDUITS
The incidence of graft failure is different for the various types of conduits used in CABG (Table 1) .
It must also be acknowledged that the completeness of follow-up, the year of the study, the selection criteria, and the definition of graft patency vary considerably among the studies, so that the completeness of the angiographic evidence is far from optimal. Also, it has been shown that arterial grafts can undergo reversible diffuse spasm (string sign) that can mimic occlusion but subsequently dilate because of changes in the hemorheologic conditions or progression of the severity of the native coronary stenosis.
Great Saphenous Vein
The patency of saphenous vein grafts (SVGs) at 1 year has been reported to range from 81% to 98%. 1, 2 Of particular note, a follow-up analysis of the 1 modern trial, the PREVENT IV (Project of Ex Vivo Vein Graft Engineering via Transfection IV), reported SVG patency of only 75% at 12 to 18 months. 3 This disappointing patency rate in a contemporary series may be, at least in part, because of a selection bias induced by the availability of percutaneous techniques (with patients having more diffuse disease undergoing CABG). Midterm patency of SVGs, between 5 and 7 years, has been reported to be 75% to 86%. 1, 2, 4, 5 Late SVG patency is severely reduced at ≥10-year follow-up, with studies reporting patency rates of 55% to 60%. 1, 6 A large VA trial (Veterans Affairs) assessed SVG and left internal thoracic artery (LITA) graft patency in 1074 and 457 patients, respectively. The 10-year patency was 61% for veins and 85% for arterial grafts (P<0.001). If a graft was patent at 1 week, then that graft had a 68% (SVG) and 88% (LITA) chance of being patent at 10 years (P<0.001). 6 A network meta-analysis comparing all conduits used for CABG has shown that, compared with the radial artery (RA) and right internal thoracic artery (RITA), SVGs have a 3-to 4-fold higher risk of occlusion after 4 years. 4 The attrition rate of SVG is 1% to 2% per year between 1 and 6 years and 4% per year between 6 and 10 years. 7 It must be noted that different strategies have now been proposed to improve SVG patency, and it is likely that variations in surgical technique or use of specific devices may significantly improve SVG outcome.
In a small randomized controlled trial, the use of an atraumatic harvesting technique, defined as harvesting the SVG with a fat pedicle and avoidance of overdistension, reported excellent long-term patency rates (83% at 16 years). These results were significantly better than those of conventionally harvested SVG and similar to those of the LITA. 8 Similarly, in another small randomized controlled trial, SVG grafts anastomosed proxi- Finally, preliminary evidence indicates that at 1-year of follow-up, the use of external stents to support SVG grafts can significantly improve hemodynamic flow within vein grafts by reducing turbulence, which in turn reduces intimal hyperplasia. 10 Whether this will translate into long-term improvements in vein graft patency, however, is still to be determined.
Internal Thoracic Artery
Since the mid-1980s, the use of the LITA for left anterior descending artery (LAD) grafting has been a cornerstone of CABG surgery. The patency of the LITA at 1 year has been reported to be 93% to 96%, 6 at 5 years 88% to 94%, 2, 6 and ≥10 years 85% to 90%. 6 Tatoulis and colleagues 11 reported patency rates for the LITA and RITA at 5, 10, and 15 years to be 98% and 96%, 95% and 81%, and 88% and 65%, respectively. In this study, the LITA was predominantly targeted to the LAD, whereas the RITA was commonly grafted to the right coronary artery (RCA), followed by the circumflex territory. The lower patency of the RITA was likely because of the poorer patency of the RITA-RCA/ posterior descending artery target (overall conduit/target, patency: LITA/LAD, 97%; RITA/LAD, 95%; RITA/ RCA or posterior descending artery, 83%). 11 Progression of atherosclerosis in the distal RCA has been suggested as a possible explanation for the lower patency rate of RITA-RCA/posterior descending artery grafts. 12 Another leading mechanistic explanation is competitive flow between the graft and the native coronary circulation. Given that dominant RCAs are usually larger diameter vessels than the LAD or circumflex, a larger RCA without a high-grade proximal stenosis may continue to have substantial flow. In addition, the LAD is technically an easier target with greater outflow, which contributes to excellent LITA to LAD patency. The RITA may be used as a free graft to the left coronary system without compromising patency; for the right coronary system, the patency of free RITA is higher than of an in situ RITA.
11,12

Radial Artery
Studies of RA patency at 1 year report a 89% to 92% 2 patency rate, whereas a separate series with longerterm results describe 90% to 98% patency at 5 years. 2, 5 A meta-analysis reported RA patency beyond 4 years to be 90%. 4 Achouh and Acar 13 reported a 20-year angiographic patency of 83% and attrition rate of 0.4% per year after the first year up to 20 years. Gaudino and colleagues 14 reported 25% probability of occlusion or stenosis at 20 years for the RA compared with 19.0% for the LITA and 55.0% for SVG (P=0.002 for RA versus SVG, 0.11 for RA versus LITA, and P<0.001 for LITA versus SVG). The RAPCO trial 15 presented their late results at the 2016 American Association of Thoracic Surgery meeting. The 10-year patency of the RA was reported to be 89% to 91%. An important predictor of early and late patency for the RA is the severity of proximal native disease. 16 
Right Gastroepiploic Artery
There are limited data regarding right gastroepiploic artery patency. Early 1-year patency was reported to be 92% to 97%, 17 80% to 90% at 5 years, 18 and 62% at 10 years. 18 These relatively low long-term patency rates are improved by using skeletonization and more restrictive criteria for target vessel stenosis (95% and 90% cumulative patency rates at 5 and 8 years, respectively). 17 In conclusion, the incidence of graft failure varies with the type of conduits used for CABG. Arterial grafts have higher patency rates compared with SVGs, especially at long-term follow-up.
BIOLOLGICAL MECHANISMS UNDERLYING GRAFT FAILURE
Because graft failure is significantly more common in venous than arterial grafts, most of the known pathological mechanisms have been described in SVGs. Graft failure describes total graft occlusion that prevents blood flow through the graft to the revascularized part of the heart. In this regard, it differs from minor intimal hyperplasia, which is almost universally seen in implanted grafts months to years after surgery. However, the underlying mechanisms can vary, particularly in the early versus late stages after implantation. The pathophysiology of vein graft failure has been attributed to acute thrombosis within the first month, intimal hyperplasia up to 1 year, and atherosclerosis beyond 1 year (Figure 1) . 19 Different mechanisms are associated with each time frame; however, all contribute to graft occlusion.
Early failure is predominantly attributed to technical factors but can also be conduit-related (eg, mismatch in conduit size or preexisting graft pathology) or because of extrinsic factors, such as hypercoagulability, all of which can result in acute thrombosis and failure. In the first months after surgery, neointimal hyperplasia may present initially at the anastomotic sites, followed by generalized neointimal hyperplasia and atherosclerotic degeneration years after surgery. 19 Contrary to the native coronary vessels, atherosclerosis in vascular grafts (particularly SVGs) is an accelerated process, with almost all SVGs showing some degree of intimal hyperplasia 1 year after surgery. Moreover, atherosclerosis in vascular grafts is characterized by a concentric and diffuse pattern, whereas the fibrous cap is often less well defined than that of coronary atheromas and therefore more prone to rupture. This finding highlights significant differences in the pathophysiology of atherogenesis between native vessels and vascular grafts.
20,21
Mechanisms of Acute Thrombosis
Early graft failure may be caused by acute thrombosis, secondary to either direct endothelial injury or endothelial activation, leading to a prothrombotic phenotype. 22 De-endothelialization as a result of mechanical forces is predominantly seen in free grafts, such as SVGs. 23 This results in exposure of the underlying extracellular matrix, local release of tissue factors, and reduced bioavailability of prostacyclin and nitric oxide (NO), all of which contribute to enhanced platelet activation, deposition of fibrin, and ultimately thrombus formation. 24 At the same time, activated platelets express several prothrombotic molecules on their surface, such as P-selectin, and secrete substances with potent paracrine effects, such as platelet-derived growth factor, von Willebrand factor, and the CD40 ligand, all promoting thrombosis and local inflammation through leukocyte chemotaxis and vascular wall infiltration. 22 Endothelial cells may 
Impaired Endothelial Function
The vascular endothelium is the source of a number of molecules with either vasorelaxant (eg, NO) or vasoconstrictive (eg, endothelin) properties, the balance of which ultimately regulate the vascular tone. 25, 26 However, NO exerts pleiotropic effects by regulating the vascular tone through activation of guanyl-cyclase in the underlying vascular smooth muscle cells (VSMCs), suppressing local inflammation, suppressing thrombosis, and protecting against oxidative injury. 26 It is interesting to note that NO bioavailability appears to be greater in arterial compared with venous grafts, providing a possible explanation for the better outcome rates observed with arterial grafts. 27 However, endothelial function varies even among different arterial types, 25 with higher endothelial NO synthase expression partly explaining the greater NO-mediated vasorelaxations in internal thoracic arteries (ITAs) compared with an RA grafts. 28 Nevertheless, recent evidence suggests that high endothelial NO synthase expression is not necessarily beneficial, given that in the presence of high levels of oxidative stress, depletion of the endothelial NO synthase cofactor tetrahydrobiopterin can result in endothelial NO synthase uncoupling and an increased production of superoxide (O 2 -) anions, resulting in endothelial dysfunction.
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Vasoconstriction and Spasm
Both arterial and vein grafts are susceptible to the effects of vasoactive substances, such as endothelin, TXA 2 , serotonin, and α1 agonists. 30 These vasoconstrictors either are from the systemic circulation (including platelets) or are generated inside the vascular wall by endothelial cells, VSMCs, or infiltrating inflammatory cells. 25 However, the response of different conduits to vasoconstrictors varies, highlighting the biological heterogeneity of the different conduits used in CABG. 25 For example, variations in the presence and relative dominance of adrenergic receptors in VSMCs may explain why certain conduits (ie, RA) are more prone to vasospasm than others. 25 
Other Biological Factors: The Role of Oxidative Stress and Morphological Characteristics
The effects of the vascular redox state on vascular disease are well documented, and several studies have implicated the production of reactive oxygen species in disease progression in both arterial and vein grafts. 31 Reactive oxygen species possess direct deleterious effects on the vascular wall and upregulate vascular inflammation through the activation of redox-sensitive proinflammatory pathways. 32 The relative absence of endogenous antioxidant protective mechanisms in SVGs compared with ITAs might also contribute to their poorer patency rates. 31 Structural characteristics of arterial and venous conduits have also been linked to their susceptibility to graft failure. For example, the relative absence of an internal elastic lamina in combination with high intercellular junction permeability in SVGs accelerates atherosclerosis through infiltration by circulating leukocytes and lipoprotein deposition. 23 In addition, exposure to the high pressure of arterial circulation results in early, diffuse intimal thickening as a compensatory response, termed "arterialization." 33 However, variations in the wall structure of arterial grafts (eg, muscular wall phenotype in RA grafts compared with a more elastic phenotype in ITA) might also explain differences in patency rates with different graft types.
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SYSTEMIC ATHEROSCLEROTIC RISK FACTORS
Most systemic risk factors have deleterious effects on local vascular biology and promote a proatherogenic phenotype. In addition, other systemic factors (eg, platelet reactivity, age) might affect the individual response to medical therapy after CABG, therefore increasing the risk for early or late graft failure because of either thrombosis or atherosclerosis. 35 Diabetes mellitus is associated with persistent platelet activation, endothelial dysfunction, increased VSMC reactivity to vasoconstriction, and accelerated intimal hyperplasia in SVG. 36, 37 The impact of diabetes mellitus on arterial and venous grafts has been investigated by several authors, with most 2, 38 but not all 39, 40 showing a detrimental effect on graft patency. In a subanalysis of the RAPS (Radial Artery Patency Study), Desai and colleagues 38 16 showed that in patients with diabetes mellitus, the proportion of complete graft occlusion was significantly lower for RA grafts than for SVGs (P=0.0004), whereas this was not true for patients without diabetes mellitus (P=0.19). The interaction between diabetic status and conduit type was also statistically significant (P=0.02).
Harskamp and colleagues 40 recently evaluated the determinants of ITA graft stenosis or occlusion in a cohort of 1539 patients receiving CABG undergoing angiographic follow-up from the PREVENT IV trial. Surprisingly, the only patient-specific predictor of ITA graft failure was the absence of diabetes mellitus (odds ratio [OR], 1.86; CI, 1.22-2.81; P=0.004) because these patients may have more severe proximal coronary artery stenosis. In addition, in a study involving 3715 angiograms, Shah and colleagues 39 failed to show an association between diabetes mellitus and graft stenosis ≥80% (OR, 1.12; CI, 0.81-1.55; P=0.5).
Because most of the clinical trials on CABG mainly enrolled men, the role of sex is difficult to evaluate. However, because of difference in vessel size and hormonal milieu, it is possible to speculate that the graft patency rate can be different in men and women. Also, an influence of sex on patency based on the type of conduit used has been suggested. In the quoted subanalysis of the RAPS trial, RA graft occlusion at 1 year occurred in similar proportions of men (8.6%) and women (5.3%) (P=0.6), whereas occlusion rates for the SVG were 12.0% and 23.3%, respectively (P=0.02). 38 In the same study, traditional cardiovascular risk factors, such as age, preoperative myocardial infarction, hypertension, elevated lipids, smoking status, and peripheral vascular disease, were not predictive of 1-year graft occlusion. However, in the more recent 5-year report of the same trial, female sex (OR, 2.23; CI, 1.14-4.38; P=0.02), smoking history (OR, 1.49; CI, 1.01-2.21; P=0.047), and elevated creatinine levels (OR, 1.17; CI, 1.02-1.35; P=0.03) were found to be independent predictors of graft occlusion. 38 A large angiographic series found no association between the classic atherosclerotic risk factors and graft patency. 39 However, in the 10-year angiographic VA study, age (acceleration factor, 1.28; CI, 1.04-1.58; P=0.02), cholesterol levels (acceleration factor, 0.76; CI, 0.60-0.96; P=0.02), and Canadian Functional Class II-IV (acceleration factor, 0.64; CI, 0.40-1.02; P=0.05) were predictors of long-term graft status. 6 Finally, in a subanalysis of the PREVENT IV trial, cerebrovascular disease (a surrogate of the severity of the atherosclerotic burden) was the only systemic predictor of graft patency (OR, 1.35; CI, 1.04-1.77; P=0.03). 3 In conclusion, the classic cardiovascular risk factors, particularly diabetes mellitus, seem to play a role in determining graft failure, although the correlation between individual risk factors and graft outcome needs further investigation.
CLINICAL CONSEQUENCES OF GRAFT FAILURE
The association between graft failure and adverse clinical outcome(s) has not been as clearly proven as commonly believed. In fact, different studies have reported discordant results. Again, differences in study size and design as well as in follow-up and definition of failure are the most likely explanation for these discrepancies.
Lytle et al 41 compared long-term survival of a cohort of 1296 patients with (723) and without (573) SVGs stenosis. At a mean follow-up of 6.9 years, patients with vein graft stenosis occurring within 5 years and patients with no vein graft stenosis had similar outcomes. However, patients with significant stenosis in SVGs to the LAD had higher rates of death and cardiac events.
In a large angiographic study of >5000 grafts, vein graft patency and occlusion were closely correlated with the need for reoperation and survival. 1 An analysis from the Duke Cardiovascular Databank reported the clinical impact of early vein graft failure in 1243 patients who underwent angiography after CABG. 42 The investigators found that SVG graft stenosis or occlusion was associated with death, myocardial infarction, or revascularization (P<0.0001 for all).
The results of the long-term follow-up of the PRE-VENT IV trial showed that SVG stenosis or occlusion was associated with an increase in revascularization but not with death or myocardial infarction. 43 In the same trial, LITA-to-LAD failure was associated with a significantly higher incidence of acute clinical events, mostly as a result of a higher rate of repeat revascularization (hazard ratio, 3.92; CI, 2.30-6.68; P<0.0001). 40 In a large angiographic study, Shavadia and coauthors 44 found that LITA-to-LAD graft stenosis ≥70%, but SVG failure was associated with a worse long-term prognosis.
In an analysis of the RAPS trial examining late angiographic follow-up, Yamasaki and coauthors 45 found that the incidence of adverse clinical events and need for revascularization were significantly higher in patients with graft stenosis (P<0.0001 and P<0.0009, respectively). The lack of a consistent correlation between graft failure and clinical event is likely related to the different amount of myocardium supplied by the failed graft. Another possible explanation is the high rate of nonflow-limiting stenosis bypassed when using standard angiography for planning the grafting strategy and the possible development of a collateral network from other patent grafts.
In conclusion, the clinical consequences of graft failure seem to vary according to the location of the distal anastomosis, with failure of grafts to the LAD more closely related to clinical events. Further investigation is required to clarify the correlation between graft occlu-sion and clinical outcome and to elucidate the pathophysiologic mechanisms of this correlation.
PHARMACOLOGICAL PREPARATION AND GRAFT STORAGE
Few studies have correlated the vasodilatory protocol used for graft preparation with patency.
Yoshizaki and coworkers 46 reviewed angiographic results among 116 patients receiving CABG who had RA grafts and were treated with either verapamil-nitroglycerin or papaverine. The results showed that papaverine was significantly associated with RA graft occlusion. Among patients randomized to either continue or suspend diltiazem therapy 1 year after RA grafting, Gaudino and colleagues 47 showed that at 5-year follow-up, no difference in angiographic patency rates among groups occurred.
The solutions in which grafts are stored before use also play an important role. Storage includes normal saline, blood-based, heparinized, and bufferedsolutions. Numerous studies demonstrate the detrimental effect of normal saline solutions on endothelial function and clinical outcomes. Wise and colleagues 48 showed that grafts stored in normal saline have significantly reduced endothelial-dependent and endothelial-independent vasodilation (P=0.005 and P=0.002, respectively). Follow-up data from the PREVENT IV trial showed that 1-year vein graft failure rates, defined as significant stenosis or occlusion, were significantly lower when buffered saline, instead of saline or blood, was used (OR, 0.63; CI, 0.49-0.79; P<0.001 and OR, 0.63; CI, 0.48-0.81; P<0.001, respectively). 49 In the PREVENT IV trial, ex vivo treatment with edifoligide (an E2F decoy that regulates expression of genes controlling smooth muscle cells [SMC] proliferation) was ineffective in the prevention of early vein graft failure. 50 Preoperative pharmacological treatment with vitamin C and cerivastatin have been reported to achieve maximal vasodilatation and endothelial preservation of the RA.
Although the pressure used to distend grafts has been shown to correlate with the degree of inflammation and the expression of endothelial adhesion molecules, 51, 52 no study to date has investigated the correlation between distension pressure and graft patency.
Finally, it was recently shown that RA grafts previously used for access during transradial coronary procedures have impaired endothelial function and suboptimal midterm patency rates. 53 Those arteries should not be used for CABG.
To summarize, the protocol used for graft preparation and storage has the potential to influence graft outcome. Buffered storage solutions and low-pressure distention seem to lead to better patency rates, but further investigation is required. 56 Although in both studies these differences lost statistical significance when analyses were limited to the randomized trials, this could be related to the reduction in statistical power because a trend toward higher graft failure in the endoscopic group was present even in the randomized subgroup. The most plausible explanation for these reported differences is the higher degree of damage to the vascular wall induced by endoscopic harvesting, although not all the studies are concordant on this issue. 57 It is important to note that studies have reported equivalent clinical outcomes in patients operated using an endoscopic versus open saphenous vein harvesting technique. 58 However, in view of the recognized lack of a strict correlation between clinical outcomes and graft patency, the angiographic data seem more relevant in clarifying this issue. Intuitively, the ongoing REGROUP trial (Randomized Endo-Vein Graft Prospective) should clarify this issue.
TECHNICAL FACTORS
A no-touch technique of SVG harvesting that reduces endothelial injury has shown superior long-term patency when compared with conventional harvesting, 8 although skeletonized ITA and RA conduits have been reported to be noninferior to pedicled grafts with respect to patency. 59, 60 Controversy still exists on the effect of on-versus off-pump surgery on patency rates. The ROOBY trial randomized 2203 patients to on-or off-pump CABG. At 1-year follow-up, angiographic patency rates of the off-pump group were significantly lower than those of the on-pump group (82.6% versus 87.8%, P<0.01). 61 A smaller European randomized trial reported similar results. 62 However, 2 other small randomized trials and a post hoc subanalysis of the PREVENT IV study found no difference in patency rate between the 2 techniques. [63] [64] [65] All the meta-analyses on the subject showed a significantly higher incidence of graft occlusion among the off-pump cases. The most recent meta-analysis of randomized controlled trials pooled angiographic data on 7011 grafts and reported an OR of 1.51 for graft occlusion in the off-pump versus onpump series (CI, 1.21-1.88; P=0.002). 66 It is plausible that differences in operator experience, study design, and enrollment criteria are the reasons for the discrepancies.
Recently, 2 large randomized controlled trials showed no difference in clinical outcome between on-and offpump CABG. The GOPCABE trial (German Off-Pump Coronary Artery Bypass Grafting in Elderly Patients) and the CORONARY trial (CABG Off-or On-Pump Revascularization Study) randomized >7200 patients to 1 of the 2 revascularization strategies and found no difference in the composite outcome of death, stroke, myocardial infarction, repeat revascularization, and renal failure at 1 and 5 years between the 2 groups. 67, 68 As for the endoscopic versus open harvesting comparison, because of the lack of a direct correlation between graft patency and clinical status, it is unlikely that graft patency can be inferred from the results of clinical outcome studies.
In summary, technical factors are important in determining graft outcome. Endoscopic saphenous vein harvesting and the off-pump technique have been correlated with lower patency rates.
TARGET VESSEL FACTORS
Different quantitative and qualitative characteristics of the target coronary vessel have the potential to influence the long-term patency of bypass grafts.
The grafting of a vessel that is not significantly stenosed creates a situation in which the flow through the conduit and the native coronary artery are in competition. Arterial grafts are living conduits with high vasoactive capacity and can react with a reduction in graft flow. Low endothelial stress because of reduced flow is associated with reduced NO bioavailability, upregulation of several proatherogenic genes in the vascular wall, and a high risk of thrombosis. 69 This is also a likely putative mechanism of arterial graft string sign.
The radial and gastroepiploic arteries are most affected by competitive flow because of their higher degree of contractility and vasospastic characteristics. Numerous studies have demonstrated that radial graft patency is higher in patients with severe proximal stenosis. In a report by Gaudino and colleagues, 14 80% of very long-term (20-year) RA occlusion or string sign cases occurred in patients in whom the artery was anastomosed to coronary arteries with stenosis ≤90%, irrespective of distal anastomosis location. This also applies to the gastroepiploic artery. As stated before, Suzuki and coauthors 17 reported patency rates of 98%, 95%, and 90% at early, 5-, and 8-year follow-up when the gastroepiploic artery was anastomosed to a target vessels with >90% stenosis. This finding is in contrast to a 67% patency at 10-year follow-up when the gastroepiploic artery was anastomosed to a target vessel with <90% stenosis. 70 The ITA is also sensitive to competitive flow, although to a lesser degree than the RA. Many 71 but not all 72 published studies have found that the patency of ITA grafts is directly correlated with the degree of proximal stenosis in the coronary target. It is important to note that even when chronic native competitive flow does not affect midterm graft patency, it influences ITA diameter. 73 The resistance of SVG appears negligible, and therefore the pressure at the distal graft anastomosis is nearly equal to the aortic pressure, with minimal risk of developing competitive flow. SVG also lacks the ability to regulate blood flow to the coronary territory and exhibit reduced variations in graft flow. For this reason, competitive flow is a significant issue for arterial rather than venous grafts.
This concern is recognized in the 2011 American College of Cardiology/American Heart Association Guideline for Coronary Artery Bypass, in which arterial grafting is contraindicated in patients with less than subocclusive stenosis of the native vessel. 74 Because of the high percentage of nonflow limiting stenosis that has been judged as functionally significant on the basis of conventional angiography, 48 a more frequent application of preoperative real functional studies may have the potential to significantly increase graft patency rates, especially for arterial conduits.
Another crucial factor determining long-term patency of the graft is target vessel diameter. Goldman and colleagues 6 examined the 10-year patency rates of SVG and found that if the target vessel diameter was >2.0 mm, SVG patency was 88%, compared with a patency rate of 55% if the target vessel diameter was ≤2.0 mm (P<0.001). In a report by Shah and coworkers 39 that explored determinants of SVG failure, defined as ≥80% stenosis, a smaller target coronary vessel diameter significantly affected graft patency (1.0-1.4 mm, P<0.001). Similarly, in a small randomized controlled trial, Souza and coauthors 75 found that a target vessel diameter ≥2.0 mm significantly increased the graft patency rate (OR, 4.7; CI, 1.4-15.4; P=0.011).
Evidence also indicates that diffuse coronary artery disease is more associated with lower graft patency than focal disease. One study using fractional flow reserve to characterize diffuse versus focal lesions found that the former was associated with an increased risk of graft failure within 6 months of CABG (26% versus 7%, P=0.021). 76 Diffuse atherosclerosis not only more adversely affects vasomotor regulation of the coronary target but also limits the availability of an adequate landing zone for the bypass conduit.
Graft patency rates are also significantly lower in stented coronary arteries compared with those not previously instrumented. 77 Distal microembolization from the failed stent, but also stent-induced chronic inflammatory response with consequent downstream endothelial dysfunction and intimal hyperplasia, are possible explanations for this finding.
Extensive calcification of the coronary target has major implications for graft failure. In addition to the adverse effect on vasomotor properties and the limited areas for anastomosis described earlier, severely calcified plaques are not amenable to suturing without performing extensive endarterectomies that significantly alter the architecture of the coronary artery.
In conclusion, target vessel factors can significantly impact graft patency. The potential for competitive flow to adversely impact graft patency is particularly important for arterial rather than venous grafts. Target vessel diameter, extent of atherosclerotic burden, calcification, and previous endovascular interventions all have the potential to influence graft patency.
INTRAOPERATIVE GRAFT ASSESSMENT AND PATENCY
Transit-time flow measurement (TTFM) is the most commonly used method for intraoperative graft verification in coronary surgery.
The current guidelines of the Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery suggest that TTFM should be considered for direct intraoperative quality control in CABG surgery (class IIa level of evidence C). 78 The most important TTFM flow variables are the mean graft flow (ml/min) and the pulsatility index (PI). The PI is obtained by dividing the difference between the maximum and minimum flow by the value of the mean flow. Any factor that increases the resistance to graft flow increases the PI value.
According to the European Task Force, the cutoff value to detect graft malfunction should be 20 mL/min for mean graft flow and 5 for PI, but different values have been reported by other authors (Table 2) . [78] [79] [80] [81] [82] [83] [84] [85] TTFM is characterized by a fairly high specificity but a poor sensitivity. 86 Standardization of factors, such as the systemic arterial pressure at which measurements are taken and the position of the probe, is extremely important to increase TTFM sensitivity. 86 Limited evidence exists on the correlation between TTFM values and graft patency because most published studies have clear selection bias, used different definitions and cutoff values, and had different follow-up. Also, all the studies are probably underpowered to detect moderate correlations. A small randomized study on the subject showed that routine TTFM does not improve 1-year graft patency but did find a significant correlation between low TTFM flow and graft occlusion at 1 year. 87 A retrospective angiographic analysis of 2 randomized controlled trials, the BBS (Best Bypass Surgery) trial and the CARRPO (Copenhagen Arterial Revascularization Randomized Patency and Outcome) trial on 982 grafts, found a 4% decrease in the odds of graft failure for every 1 mL/min increase in mean graft flow (OR, 0.96; CI, 0.93-0.99; P=0.005). 88 The lack of sensitivity with this method may be partially overcome by increasing the myocardial oxygen with a bolus of 20 μg/kg of dobutamine. 80 This method can be especially helpful in competitive flow situations or in the case of dynamic flow diversion.
Integration with intraoperative imaging (Figure 2 ) to visualize the anastomosis morphology is another means of increasing TTFM sensitivity. It has been demonstrated that when TTFM is coupled with high-resolution ultrasound imaging, the diagnostic accuracy can increase to 100%. 85 Fluorescence coronary angiography using indocyanine green is another imaging method for intraoperative evaluation of graft function that can potentially be coupled with TTFM, but few data have been reported to date. 89 Finally, intraoperative angiography in a hybrid room setting allows gold-standard intraoperative graft verification. However, obvious logistic factors limit the routine use of this method. It must also be noted that cases of transient angiographic abnormalities because of anastomotic edema in the period immediately after surgery have been described, further limiting its diagnostic application in this setting. 90 In summary, TTFM is an important tool to evaluate graft function intraoperatively and can potentially predict long-term graft patency. However, concomitant use of imaging techniques or pharmacological tests is necessary to improve TTFM accuracy.
Although TTFM is an important guide, the decision of whether to revise a graft should be based on the mean graft flow and PI values as well as surgical and anatomic considerations.
SECONDARY PREVENTION
Postoperative antiplatelet and lipid-lowering agents continue to be the mainstay of secondary prevention CABG indicates coronary artery bypass graft; HR-ECUS, high-resolution epicardial ultrasonography; LIMA, left internal mammary artery; MACE, major adverse cardiac events; MGF, mean graft flow; NPV, negative predicted value; OR, odds ratio; PCI, percutaneous coronary intervention; %BF, percentage backward flow; PI, pulsatility index; PPV, positive predicted value; RIMA, right internal mammary artery; ROC, receiver operating characteristic; TnI, troponin I; and TTFM, transit-time flow measurement. after CABG surgery. Inhibition of platelet activation after CABG helps maintain graft patency and prevent atherothrombotic complications. According to a recent American Heart Association scientific statement on secondary prevention after CABG surgery, 91 aspirin should be administered preoperatively and within 6 hours after CABG in doses of 81 to 325 mg daily. It should then be continued indefinitely to reduce graft occlusion and major vascular events (Class I, Level of Evidence A; IA). 91 For patients treated with aspirin, current guidelines recommend continuing antiplatelet therapy before surgery, except for patients at high bleeding risk. However, limited randomized evidence supports 1 strategy over the other. 92 The recently published ATACAS trial (Aspirin and Tranexamic Acid for Coronary Artery Surgery) showed no beneficial effect of the preoperative administration of aspirin 100 mg on postoperative thrombotic and hemorrhagic complications and death. 93 However, the high rate of death and thrombotic complications (particularly nonfatal myocardial infarction, detected within the first 30 days after CABG: 13.8% versus 15.8% in the aspirin versus the placebo group, respectively; RR, 0.87; CI, 0.71-1.07; P=0.20) outlines the limitations of current antithrombotic strategies and emphasizes the need for additional clinical studies.
A discrepancy exists between current US and European guidelines on the recommended dose of aspirin for long-term treatment after CABG. The former suggest considering a higher (325 mg daily) rather than a lower (81 mg daily) aspirin dose, "presumably to prevent aspirin resistance" (Class IIa, Level of Evidence A; IIaA), whereas the latter recommend low-dose (75-100 mg ACI indicates acoustic coupling index; ACS, acute coronary syndrome; BPM, beats per minute; D, diastolic blood pressure; DF, diastolic filling; HR, heart rate; LAD, left anterior descending artery; LIMA, left internal mammary artery; M, mean arterial pressure; MGF, mean graft flow; PCI, percutaneous coronary intervention; PI, pulsatility index; POST DOBU, post dobutamine; and S, systolic blood pressure. Data courtesy of Professor G. Di Giammarco. daily) aspirin in all patients (IA). The rationale underlying the recommended use of low-dose aspirin is related to selective inhibition of platelet TXA 2 production (a product of COX-1 activity) with no interference with vascular prostacyclin biosynthesis (a product of COX-2 activity), an important mechanism of endothelial thromboresistence. 94 Aspirin resistance is an ill-defined phenomenon, largely explained by noncompliance, a pharmacodynamic interaction of some nonsteroidal anti-inflammatory drugs with low-dose aspirin, or reduced systemic bioavailability of some enteric-coated formulations. 94 None of these causes of aspirin resistance would be affected by a higher dose of aspirin. Moreover, prescribing aspirin 325 mg daily for long-term treatment would not produce any additional benefit (because of the saturability of platelet COX-1 inactivation at doses as low as 30-50 mg daily), while exposing the patient to unnecessary gastrointestinal damage and undue bleeding complications, as well as to potential negative interactions with angiotensin-converting enzyme inhibitors and ticagrelor, a reversible P2Y12 blocker. 94 A more likely explanation for the impaired efficacy of low-dose aspirin in the early postoperative CABG period is the transient increase in platelet turnover 95, 96 that may limit the duration of platelet TXA 2 inhibition because of accelerated renewal of the drug target. Consistent with this hypothesis, 2 independent studies have shown that multiple daily doses of aspirin (81 mg qid or 100 mg bid) overcome impaired platelet inhibition in response to a conventional oncedaily regimen and are more effective in suppressing platelet TXA 2 production than higher doses (200-325 mg) 4 to 7 days after CABG surgery. 95, 96 Clearly, a randomized clinical trial is needed to test the hypothesis that more frequent aspirin dosing reduces premature graft occlusion and prevents major vascular events.
In summary, although the US guidelines recommend using aspirin 325 mg daily for a period after SVG, 91 the totality of the evidence 97 as well as safety considerations emphasized by the European guidelines 78 strongly support the use of low-dose aspirin in this context.
Following off-pump CABG, dual antiplatelet therapy is recommended for 1 year with low-dose aspirin (81-162 mg daily) and clopidogrel (75 mg daily) to reduce graft occlusion (IA). Dual antiplatelet therapy for 1 year after on-pump CABG may be considered in patients without recent acute coronary syndrome, but the benefits are not well established (Class IIb, Level of Evidence A; IIaA). After completion of the PLATO study (Platelet Inhibition and Patient Outcomes), a phase-3 trial of ticagrelor versus clopidogrel in aspirin-treated patients with acute coronary syndrome, 98 the investigators performed a post hoc analysis of the 1261 patients who underwent CABG within 7 days of receiving treatment. 99 In this subgroup, ticagrelor was associated with a nonsignificant reduction in the primary end point at 1-year compared with clopidogrel (10.6% versus 13.1% respectively; HR, 0.84; CI, 0. 99 However, no additional studies have examined prospectively the potential superiority of ticagrelor or prasugrel versus clopidogrel in a representative population of patients undergoing CABG. Finally, we recommend that low-dose aspirin be used instead of 325 mg for any patient concomitantly treated post-CABG with a P2Y12 inhibitor, including those with SVG bypass, because this strategy is associated with optimal efficacy and safety of dual antiplatelet therapy. 78, 100 Elevated low-density lipoprotein (LDL)-cholesterol levels accelerate the process of SVG disease after CABG by favoring the development of intimal hyperplasia and atheromatous plaques. Statins are highly effective in reducing plasma LDL-cholesterol concentrations independently of the baseline level. Moreover, their efficacy and safety in reducing important vascular outcomes have been convincingly established by numerous randomized clinical trials in ≈174 000 patients with coronary artery disease and a meta-analysis of their individual data. 101 Overall, in this meta-analysis, among the 27 trials included, statins reduced the risk of major vascular events by 21% for each mmol/L reduction in LDL-cholesterol (RR, 0.79; CI, 0.77-0.81; P<0.0001), with significant reductions in both women and men. Moreover, similar proportional reductions in risks of major vascular events per mmol/L LDL-cholesterol reduction independent of the baseline characteristics of the randomized participants, including pretreatment LDLcholesterol level, history of CHD, and estimated 5-year risk of major vascular events were demonstrated. 101 Statins have been shown to reduce the development of SVG disease by inhibiting neointimal formation and VSMC proliferation. Thus, the post-CABG trial demonstrated that lowering LDL-cholesterol levels to <100 mg/ dL reduced both cardiovascular events and the progression of atherosclerosis in native coronary arteries and SVG (27% versus 39% aggressive versus moderate cholesterol-lowering treatment, respectively; P<0.001). 102 Although the benefits of more aggressive lipid lowering by high-intensity statin therapy to LDL levels <70 mg/dL in further reducing the risk of major vascular events are well established, 101 specific data on patients undergoing CABG are sparse, and further research is needed.
Despite the solid evidence supporting the efficacy and safety of long-term statin therapy, 101 it remains underused after CABG with declining patient adherence. According to the quoted American Heart Association statement, all patients receiving CABG should receive long-term statin therapy, starting in the preoperative period and restarting early after surgery in the absence of contraindications (IA). 91 High-intensity statin therapy (eg, atorvastatin 40-80 mg, rosuvastatin 20-40 mg daily) should be administered after CABG surgery to all patients <75 years of age (IA). Moderate-intensity statin therapy should be prescribed to those patients who are intolerant of high-intensity therapy and to those at greater risk of drug-drug interactions, such as patients >75 years of age receiving CABG (IA). Although CABG using arterial grafts might be associated with a lower degree of downstream coronary and conduit disease progression, evidence does not suggest that this may dictate a different approach to secondary prevention.
Enrollment in a structured cardiac rehabilitation program should be considered because it can enhance patient compliance with the medical regimen and promote lifestyle changes, including regular physical exercise and smoking cessation, and it allows for dietary counseling. 100 Smoking cessation is a highly effective measure to reduce morbidity and mortality in patients after acute coronary syndrome. Although evidence shows that smoking can be detrimental to SVG remodeling, 103 no studies have correlated smoking after surgery with graft patency.
Finally, it should be emphasized that tight glycemic control (ie, maintaining serum glucose ≤200 mg/dL) in patients with diabetes mellitus receiving CABG improves perioperative outcomes and decreases recurrent ischemic events.
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Conclusions
Graft failure is a complex phenomenon that occurs in a substantial proportion of CABG conduits. Biological mechanisms, target vessel characteristics, surgical technique, and type of graft used all play a role in determining failure. The correlation between atherosclerotic risk factors and graft patency needs further investigation. The clinical consequences of graft failure seem to be dependent on the type and location of the failed graft and are still poorly characterized. Pharmacological prevention with antiplatelet and lipid-lowering agents is associated with better clinical outcome after CABG and has the potential to reduce the incidence of graft occlusion. Finally, further studies are needed on the possibility that intraoperative assessment of graft flow by TTFM and other imaging techniques can reduce the incidence of graft failure. 
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